Shanghai - WuXi Giant promise (HK: 2126), an independent innovative biotechnology company focused on the R&D, production and commercialization of cellular immunotherapy products, announces that it has launched JWATM214 is used in clinical research for the treatment of advanced hepatocellular carcinoma (HCC), and the reinfusion treatment of the first patient has been completed.

Primary liver cancer is a common malignant tumor of the digestive system worldwide, with a high degree of malignancy and poor prognosis. The pathological type of primary liver cancer is mainly HCC, accounting for 85% to 90% of primary liver cancer. China is the country with the highest incidence and mortality rate of primary liver cancer in the world, with 466,000 new cases and 422,000 deaths each year. Based on available treatment options, patients have a median progression-free survival of approximately 6 months after first- and second-line therapy, with limited benefit. Therefore, there is an urgent need to develop effective treatments for patients with recurrent and metastatic advanced HCC.

This study is the first human study of JWATM214, aiming to evaluate the safety and tolerability of JWATM214 in adult patients with advanced HCC positive for GPC3 expression, and to determine the phase II recommended dose (RP2D). Pharmacokinetic characteristics, and preliminary observation of curative effect.

Glypican-3 (GPC-3) is overexpressed in many malignant tumors such as HCC, and has become a target for diagnosis and treatment of HCC. Previous literature reports have preliminarily confirmed the feasibility of T cell immunotherapy targeting GPC-3 in the treatment of HCC patients. JWATM214 is an autologous T cell immunotherapy candidate drug targeting GPC-3 independently developed by WuXi Juro based on Eureka's ARTEMIS platform and Lyell's T cell anti-exhaustion technology. It combines the advantages of high affinity and high specificity of GPC-3 monoclonal antibody, and on the basis of JWATM204, it adds cJun protein regulation to delay T cell exhaustion, so as to obtain more durable and better anti-tumor activity, which is expected It provides a new treatment option for advanced HCC patients with positive GPC-3 expression.

In 2020, WuXi Giant Nuo reached an agreement with Eureka and Lyell respectively, and obtained the licenses of Eureka's ARTEMIS technology and Lyell's T cell anti-failure technology for use in China (including mainland China, Hong Kong, Macau) , Taiwan) and member countries of the Association of Southeast Asian Nations to develop, produce and commercialize related products.

About JWATM214

JWATM214 is an autologous T cell immunotherapy candidate drug targeting GPC-3 independently developed by WuXi Juro based on Eureka's ARTEMIS platform and Lyell's T cell anti-exhaustion technology. It combines the advantages of high affinity and high specificity of GPC-3 monoclonal antibody, and on the basis of JWATM204, it adds cJun protein regulation to delay T cell exhaustion, so as to obtain more durable and better anti-tumor activity, which is expected It provides a new treatment option for advanced HCC patients with positive GPC-3 expression.

About WuXi Juno

WuXi Giant Promise (HKEx: 2126) is an independent and innovative biotechnology company, focusing on the R&D, production and commercialization of cellular immunotherapy products, and is committed to taking innovation as the forerunner and becoming a leader in cellular immunotherapy. By. Founded in 2016, WuXi Giant Nuo has successfully built an internationally leading comprehensive product development platform for cellular immunotherapy, as well as a cellular immunotherapy product pipeline covering blood tumors, solid tumors and autoimmune diseases. WuXi Giant promise is committed to bringing hope of cure to patients in China and even around the world with breakthrough and high-quality cellular immunotherapy products, leading the healthy and standardized development of China's cellular immunotherapy industry.

Contact:

Tel: +86 21 50783699

(C) 2023 Electronic News Publishing, source ENP Newswire